Background:
- Pembrolizumab and lenvatinib in combination (pembro-lenv) has resulted in improved outcomes compared to standard chemotherapy for second-line treatment of endometrial cancer (EC)
- Lenvatinib currently is only indicated for microsatellite stable (MSS) tumors as it is associated with significant toxicities and many microsatellite instability high (MSI-H) tumors respond to pembrolizumab alone.